A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC

NCT01996306 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms

Interventions

BIOLOGICAL: Bevacizumab
DRUG: CPT-11 (Irinotecan)
DRUG: 5-FU Bolus
DRUG: 5-FU Infusion
DRUG: l-LV (dl-LV)
BIOLOGICAL: bevacizumab
DRUG: CPT-11 (Irinotecan)
DRUG: Capecitabine

Sponsor

Epidemiological and Clinical Research Information Network